Sandoz Lands EU Nod for Insulin Biosimilars Bysumlog, Dazparda
15 maj, 14:12
15 maj, 14:12
08:12 AM EDT, 05/15/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) said Friday it secured the European Commission's marketing authorization for insulin lispro biosimilar Bysumlog and insulin aspart biosimilar Dazparda to treat diabetes mellitus in adults, adolescents and children.
The injectable insulins have equivalent efficacy and comparable safety to their reference medicines, Eli Lilly's (LLY.SW, LLY.F) Humalog and Novo Nordisk's (NOVO-B.CO) NovoRapid.
The Swiss drugmaker will commercialize the biosimilar drugs in Europe and other key territories under a 2018 agreement with China's Gan &Lee Pharmaceuticals.
15 maj, 14:12
08:12 AM EDT, 05/15/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) said Friday it secured the European Commission's marketing authorization for insulin lispro biosimilar Bysumlog and insulin aspart biosimilar Dazparda to treat diabetes mellitus in adults, adolescents and children.
The injectable insulins have equivalent efficacy and comparable safety to their reference medicines, Eli Lilly's (LLY.SW, LLY.F) Humalog and Novo Nordisk's (NOVO-B.CO) NovoRapid.
The Swiss drugmaker will commercialize the biosimilar drugs in Europe and other key territories under a 2018 agreement with China's Gan &Lee Pharmaceuticals.
Nibe
Evolution
Nibe
Evolution
1 DAG %
Senast
OMX Stockholm 30
0,09%
(16:42)
OMX Stockholm 30
1 DAG %
Senast
3 057,78